Literature DB >> 10702484

Monitoring specific T-cell responses to melanoma vaccines: ELISPOT, tetramers, and beyond.

T F Gajewski1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10702484      PMCID： PMC95840          DOI： 10.1128/CDLI.7.2.141-144.2000

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  19 in total

1.  MHC-based diagnostics and therapeutics - clinical applications for disease-linked genes.

Authors:  M C Howard; E G Spack; K Choudhury; T F Greten; J P Schneck
Journal:  Immunol Today       Date:  1999-04

2.  Evaluation of the modified ELISPOT assay for gamma interferon production in cancer patients receiving antitumor vaccines.

Authors:  T Asai; W J Storkus; T L Whiteside
Journal:  Clin Diagn Lab Immunol       Date:  2000-03

Review 3.  The immunotherapy of solid cancers based on cloning the genes encoding tumor-rejection antigens.

Authors:  S A Rosenberg
Journal:  Annu Rev Med       Date:  1996       Impact factor: 13.739

4.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.

Authors:  P P Lee; C Yee; P A Savage; L Fong; D Brockstedt; J S Weber; D Johnson; S Swetter; J Thompson; P D Greenberg; M Roederer; M M Davis
Journal:  Nat Med       Date:  1999-06       Impact factor: 53.440

5.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

6.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells.

Authors:  P G Coulie; M Somville; F Lehmann; P Hainaut; F Brasseur; R Devos; T Boon
Journal:  Int J Cancer       Date:  1992-01-21       Impact factor: 7.396

Review 7.  Tumor antigens recognized by T lymphocytes.

Authors:  T Boon; J C Cerottini; B Van den Eynde; P van der Bruggen; A Van Pel
Journal:  Annu Rev Immunol       Date:  1994       Impact factor: 28.527

Review 8.  Alteration of signal transduction in T cells from cancer patients.

Authors:  A C Ochoa; D L Longo
Journal:  Important Adv Oncol       Date:  1995

9.  High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals.

Authors:  M J Pittet; D Valmori; P R Dunbar; D E Speiser; D Liénard; F Lejeune; K Fleischhauer; V Cerundolo; J C Cerottini; P Romero
Journal:  J Exp Med       Date:  1999-09-06       Impact factor: 14.307

10.  Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes.

Authors:  S L Topalian; M I Gonzales; M Parkhurst; Y F Li; S Southwood; A Sette; S A Rosenberg; P F Robbins
Journal:  J Exp Med       Date:  1996-05-01       Impact factor: 14.307
View more
  5 in total

1.  Intensity of the vaccine-elicited immune response determines tumor clearance.

Authors:  Ainhoa Perez-Diez; Paul J Spiess; Nicholas P Restifo; Polly Matzinger; Francesco M Marincola
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

2.  Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes.

Authors:  Simone Seiter; Vladia Monsurro; Mai-Britt Nielsen; Ena Wang; Maurizio Provenzano; John R Wunderlich; Steven A Rosenberg; Francesco M Marincola
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

3.  MHC class II tetramer analyses in AE37-vaccinated prostate cancer patients reveal vaccine-specific polyfunctional and long-lasting CD4(+) T-cells.

Authors:  Eleftheria A Anastasopoulou; Ioannis F Voutsas; Michael Papamichail; Constantin N Baxevanis; Sonia A Perez
Journal:  Oncoimmunology       Date:  2016-05-02       Impact factor: 8.110

4.  Guidelines for the welfare and use of animals in cancer research.

Authors:  P Workman; E O Aboagye; F Balkwill; A Balmain; G Bruder; D J Chaplin; J A Double; J Everitt; D A H Farningham; M J Glennie; L R Kelland; V Robinson; I J Stratford; G M Tozer; S Watson; S R Wedge; S A Eccles
Journal:  Br J Cancer       Date:  2010-05-25       Impact factor: 7.640

Review 5.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.